Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Flipster Secures AAA Security Rating From CER.live, Placing Among Top 13 Most Secure Global Exchanges
PANAMA CITY, Sept. 11, 2025 /PRNewswire/ -- Flipster, a fast-growing crypto perpetuals…